ObjectiveTo study the clinical application of enteral microecopharmaceutics immunonutrition in the peroperation of colorectal cancer. MethodsLiteratures about enteral microecopharmaceutics immunonutrition published in China and abroad were collected and reviewed. ResultsEarly clinical application of enteral microecopharmaceutics immunonutrition in the perioperation can greatly improve the nutritional status of patients with colorectal cancer, increase the patients' immune function, reconstruct the intestinal flora, and reduce the incidence of complications. ConclusionsThe clinical application of enteral microecopharmaceutics immunonutrition in the perioperation of colorectal cancer can obviously improve patients' nutritional status and immune function, reduce the stress response, and improve its prognosis, but the use of best dose still need further study.
ObjectiveTo investigate the expression of tumor necrosis factor-α (TNF-α) in prostate cancer tissue and explore its relations with tumor angiogenesis. MethodsThe expression of TNF-α and CD105 were detected with two-step immunohistochemical staining technique in 20 cases of benign prostatic hyperplasia and 50 cases of prostate cancer between January 2010 and January 2012, and microvessel density (MVD) marked with CD105 was also measured. ResultsThe expressions of TNF-α and CD105 were higher in prostate cancer (41.72±8.67, 20.15±2.67) than those in benign prostatic hyperplasia (21.01±3.85, 4.34±1.67) (t'=13.990, P<0.001; t'=29.771, P<0.001). TNF-α and MVD were not correlated with age and size of tumor, but were positively correlated with tumor differentiation degree (rs=0.847, P<0.001; rs=0.776, P<0.001) and negatively correlated with clinical grades (rs=-0.769, P<0.001; rs=-0.842, P<0.001). ConclusionThe result indicates that over expression of TNF-α exists in prostate cancer. It may play an important role in the anginogenesis and carcinogenesis of prostate cancer.
ObjectiveTo investigate the expression of adrenomedullin (ADM) in human liver cancer and to evaluate its clinical signigicance. MethodsA total of 54 patients with liver cancer who underwent surgery between January 2012 and November 2013 and another 18 benigh tissue samples were selected. Immuohistochemical staining (SP staining) was performed to detect the expression of ADM in liver cancer, and enzyme-linked immunosorbent assay was applied to determine the concentration of ADM in the patients and controls, and the relationship was retrospectively analyzed between the expression of ADM in liver cancer and the clinicobiological features. Besides, 60 inpatients with liver cancer and 40 health people under went physical examination between January and June 2013 were selected, whose expression of ADM in plasma was deteced. ResultsThe expression of ADM in liver cancer was significantly higher than that in the normal tissues (P<0.01). There was a significant relationship between the expression of ADM and the differentiation grade in liver cancer (P<0.05), and there was no relationship between the expression of ADM and age, histological type and American Joint Committen on Cancer (AJCC) stage (P>0.05). The expression of ADM in the plasma in liver cancer group was significantly higher than that in the control group (P<0.05). There was a significant relationship between the expression of ADM in the plasma and AJCC stage (P<0.05). ConclusionThe expression of ADM significantly increases in patients with liver cancer, which is associated with the differentiation grades of the liver cancer. ADM may play an important role in the occurrence and development of liver cancer.